Lilly Buys Stake in Zhejiang BetaPharma

Lilly has contributed to Zhejiang BetaPharma’s latest fund raising. After the private placement, the two sides will co-develop drug candidates in oncology, cardiovascular diseases and diabetes. Details of the transaction were not disclosed. Zhejiang BetaPharma’s leading candidate is Conmanna, an EGFR tyrosine kinase inhibitor, intended to target cancer. More details... Stock Symbol: (NYSE: LLY)